Pérez-Requejo J L
Br J Haematol. 1976 May;33(1):39-51. doi: 10.1111/j.1365-2141.1976.tb00970.x.
The test for platelet factor 3 described by Hardisty & Hutton (1975) has been modified to conform to the usual design for a parallel-line bioassay. Manchester Comparative Thromboplastin has been used as assay Standard, allowing an arbitrary unit of activity to be adopted. However, experiments suggested that the platelet activity measured was different from tissue factor activity. Platelets are tested as platelet-rich plasma diluted in a standardized mixture of plasma and fibrinogen, so that differences between the clotting factors of the test samples are eliminated, as verified by experiments on haemophiliacs and patients on anticoagulant treatment. Sonication and repeated freezing and thawing of platelet-rich plasma showed that approximately 15% of the PF3 is released by kaolin. In vivo, a single dose of 600 mg of aspirin reduced the PR3-release to half the previous value in 2 h; initial values were regained in 5-8 days.
哈迪斯蒂和赫顿（1975年）描述的血小板第3因子试验已作修改，以符合平行线生物测定的常规设计。已使用曼彻斯特比较凝血活酶作为测定标准，从而可以采用任意活性单位。然而，实验表明所测得的血小板活性与组织因子活性不同。血小板以富含血小板血浆的形式进行检测，该血浆用血浆和纤维蛋白原的标准化混合物稀释，这样就消除了测试样品凝血因子之间的差异，这一点已通过对血友病患者和接受抗凝治疗患者的实验得到验证。对富含血小板血浆进行超声处理以及反复冻融表明，约15%的PF3可被高岭土释放。在体内，单剂量600毫克阿司匹林在2小时内可将PR3释放量降至先前值的一半；5 - 8天内恢复初始值。
